A randomised phase II trial of adaptive image guided standard or dose escalated radiotherapy in the treatment of transitional cell carcinoma of the bladder

Radiation treatment alone or in combination with chemotherapy can cure bladder cancer. The higher the radiation dose to the tumour the higher the chances of curing the cancer, however, higher doses to surrounding normal organs increases risks of side effects. The investigators plan to use daily imaging to determine the optimal radiation treatment for a multi-centre international clinical trial comparing this approach with standard care.

Primary Sponsor

The Institute of Cancer Research (UK)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

345

Closing Date of Accrual

21st April 2020

Trial Chairperson

A/Prof Farshad Foroudi, Olivia Newton John Cancer Centre, VIC

Trial Contact

RAIDER@trog.com.au

Related Post

15 July, 2025

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT

DECREASE trial into prostate cancer
8 July, 2025

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE